Page 70 - Roby Zomer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roby zomer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roby Zomer Today - Breaking & Trending Today

Cannabis company lists in London to fund Covid trial


Cannabis company lists in London to fund Covid trial
Australia s MGC Pharmaceuticals aims to raise £5m to fund final-stage trials of anti-inflammatory Covid treatment called Artemic
1 February 2021 • 3:54pm
An Australian medicinal cannabis company is preparing to list in London to help fund clinical trials for a marijuana-derived Covid treatment.
MGC Pharmaceuticals will be just the second medical cannabis outfit to list on the London Stock Exchange, after the financial regulator changed the rules last year, paving the way for companies like MGC to raise funds with a listing.
It hopes to raise £5m to help cover the costs of final-stage clinical trials for an experimental anti-inflammatory Covid treatment called Artemic. ....

United Kingdom , City Of , Oxford Nanopore , Roby Zomer , Boris Johnson , Auction Technology Group , London Stock Exchange , Nextenergy Renewables , Dr Martens , Ta Associates , Middle East , Technology Group , Aqua Comms , Triple Point Investment , Energy Renewables , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ராபி ஜோமேற் , போரிஸ் ஜான்சன் , ஏலம் தொழில்நுட்பம் குழு , லண்டன் ஸ்டாக் பரிமாற்றம் , டாக்டர் மார்டென்ஸ் , தா கூட்டாளிகள் , நடுத்தர கிழக்கு , தொழில்நுட்பம் குழு , அக்வா கம்ஸ ,

Proactive Investors China - The web's leading portal for China stocks - MGC Pharma higher as ArtemiC Phase II clinical trial on COVID-19 patients meets all primary and secondary endpoints


2020-12-15
by Proactive Australia
MGC Pharmaceuticals Ltd s (ASX:MXC)(OTCMKTS:MGCLF)(FRA:H5O) Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment ArtemiC, based on Swiss PharmaCan AG MyCell Enhanced
TM delivery system technology, on those diagnosed with COVID-19, has met all the Phase II primary and secondary endpoints and demonstrated to improve the clinical recovery of the patients.
The European-based biopharma company specialising in the production and development of phytocannabinoid-derived medicines is now in a strong position to respond to a significant potential increase in the demand for ArtemiC in the immediate future as a supplement, and in the future as part of a Phase III study. ....

Roby Zomer , Pharmaceuticals Ltd , Artemic Phase , Swiss Pharmacan , Investigational Medicinal Product , ராபி ஜோமேற் , மருந்துகள் லிமிடெட் ,